Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation

Dabigatran has been shown to be superior to warfarin for stroke prevention in nonvalvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost effective from a societal perspective, cost implications for individual patients and in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Cardiol
Hlavní autoři: Salata, Brian M., Hutton, David W., Levine, Deborah A., Froehlich, James B., Barnes, Geoffrey D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4780215/
https://ncbi.nlm.nih.gov/pubmed/26552509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjcard.2015.09.048
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky